In this narrative review article, we discuss the putative role of GLP-1 RAs in the treatment of patients with hepatocellular carcinoma, and especially NASH-related HCC, focusing on the molecular pathways that could justify a possible benefit. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.